Press Releases

Date Title
Toggle Summary Aeglea BioTherapeutics Announces Design of Pivotal Phase 3 PEACE Trial Evaluating Pegzilarginase in Arginase 1 Deficiency
Single, Global Pivotal Trial to Support Registration; Primary Endpoint of Arginine Reduction Expected to Initiate in Q2 2019; Topline Data Anticipated in Q1 2021 Company to Host Conference Call Today at 5:00 p.m. ET AUSTIN, Texas , Dec. 11, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc.
Toggle Summary Aeglea BioTherapeutics to Present at BMO Capital Markets 2018 Prescription for Success Healthcare Conference
Company to Webcast Fireside Chat on Wednesday, December 12 at 3:40 p.m. ET AUSTIN, Texas , Dec. 06, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare
Toggle Summary Aeglea BioTherapeutics to Present at Evercore ISI HealthconX Conference
Company to Webcast Fireside Chat on Tuesday, November 27 at 2:45 p.m. ET AUSTIN, Texas , Nov. 20, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare
Toggle Summary Aeglea BioTherapeutics Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights
AUSTIN, Texas , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today reported financial results for the third
Toggle Summary Aeglea BioTherapeutics to Present Preclinical Data on a New Pipeline Therapeutic for Cystinuria in an Oral Presentation at the 2018 American Society of Nephrology (ASN) Annual Meeting
AEB5100 is an Engineered Human Enzyme with Novel Cystine Degrading Activity Presentation Today at 5:54 p.m. PT at the 2018 American Society of Nephrology (ASN) Annual Meeting AUSTIN, Texas , Oct. 26, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc.
Toggle Summary Aeglea BioTherapeutics Announces Positive Interim Clinical Data for Pegzilarginase in Advanced Melanoma Patients at the European Society for Medical Oncology 2018 Congress
Pegzilarginase Monotherapy Demonstrates Anti-Tumor Activity AUSTIN, Texas , Oct. 22, 2018 (GLOBE NEWSWIRE) --   Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases
Toggle Summary Aeglea BioTherapeutics to Present Preclinical Data on New Pipeline Therapeutic for Homocystinuria at 2018 American Society of Human Genetics (ASHG) Conference
AEB4104 is a Novel Engineered Human Enzyme with Unique Specificity for Degrading Both Homocysteine and Homocystine AEB4104 Prevents Death, Stops Disease Progression, and Reverses Liver Pathology in a Disease Model of Homocystinuria AUSTIN, Texas , Oct.
Toggle Summary Aeglea BioTherapeutics Announces New Positive Interim Clinical Data and Improvements in Disease Manifestations for Ongoing Phase 1/2 Trial of Pegzilarginase in Patients with Arginase 1 Deficiency
Pegzilarginase is Effective in Sustainably Lowering Plasma Arginine Levels Clinically Significant Improvements After Eight Doses Included Effects on Mobility and Adaptive Behavior Company to Host Clinical Update Conference Call Today at 8:30 a.m. ET AUSTIN, Texas , Oct.
Toggle Summary Aeglea BioTherapeutics to Present New Interim Phase 1/2 Clinical Trial Data in Arginase 1 Deficiency at 2018 ASHG Annual Meeting
   Company to Host Clinical Update Conference Call on October 17 at 8:30 a.m. ET Aeglea to Present Literature Review on Arginase 1 Deficiency Positive Preclinical Efficacy Data on its AEB4104 Homocystinuria Therapeutic Program AUSTIN, Texas , Oct. 10, 2018 (GLOBE NEWSWIRE) -- Aeglea
Toggle Summary FDA Grants Rare Pediatric Disease Designation to Pegzilarginase for Arginase 1 Deficiency
Aeglea Eligible to Receive a Priority Review Voucher Company Plans to Initiate Pivotal Trial in First Half of 2019 AUSTIN, Texas , Oct. 01, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme
Toggle Summary Aeglea BioTherapeutics Announces Oral Presentation of Preclinical Data on New Pipeline Therapeutic for Cystinuria at 2018 American Society of Nephrology
AUSTIN, Texas , Sept. 17, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced that it will deliver an oral
Toggle Summary Aeglea BioTherapeutics Announces Positive Interim Clinical Data and Completion of Enrollment for Ongoing Phase 1/2 Trial of Pegzilarginase in Patients with Arginase 1 Deficiency
Exceeded Enrollment Target with 15 Patients in Phase 1/2 Trial Additional Interim Data to be Presented at ASHG Conference in October 2018 Company Plans to Announce Pivotal Trial Design in Q4 2018 and Initiate Pivotal Trial in 1H 2019 Company to Host Clinical Update Conference Call Today at 8:30
Toggle Summary Aeglea BioTherapeutics to Present at 2018 Wells Fargo Healthcare Conference
Company to Webcast Presentation on Wednesday, September 5 at 10:50 am ET AUSTIN, Texas , Aug. 28, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic
Toggle Summary Aeglea BioTherapeutics to Present New Interim Phase 1/2 Clinical Trial Data in Arginase 1 Deficiency at 2018 SSIEM Annual Symposium
Company to Host Clinical Update Conference Call on September 4 at 8:30 a.m. ET AUSTIN, Texas , Aug. 27, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare
Toggle Summary Aeglea BioTherapeutics Provides Corporate Update and Reports Second Quarter 2018 Financial Results
AUSTIN, Texas , Aug. 09, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today provided a corporate update and reported